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Little is known about the immune response to noroviruses. To elucidate the immunobiology of norovirus
infection in humans, 15 volunteers were challenged with Snow Mountain virus (SMV), a genogroup 2 noro-
virus. We assessed the cellular and humoral immune response and infection by analyzing stool, serum, saliva,
and peripheral blood mononuclear cell (PBMC) responses pre- and postchallenge. In contrast to Norwalk virus
(NV), SMV infection was not dependent upon blood group secretor status. Nine of 15 volunteers were infected
and showed a >4-fold increase over the prechallenge anti-SMV serum immunoglobulin G (IgG) titer, mostly
subclass IgG1. Although serum IgG elicited by SMV infection was cross-reactive with Hawaii virus (HV),
another genogroup 2 norovirus, salivary IgA was less cross-reactive. Neither SMV-elicited serum IgG nor
salivary IgA cross-reacted with NV, a genogroup 1 norovirus. Significant increases in serum gamma interferon
(IFN-) and IL-2, but not IL-6 or IL-10, were noted on day 2 postchallenge. For the majority of volunteers, both
infected and uninfected, PBMCs stimulated with norovirus virus-like particles secreted IFN- and other Th1
cytokines, suggesting previous norovirus exposure in most volunteers. Like the IgG antibodies, the SMV-
activated T cells were cross-reactive with HV but not NV. IFN- production was dependent upon CD4 cells,
consistent with a predominant, but not exclusive, Th1 response. To our knowledge, this is the first report
characterizing T-cell and cytokine responses following live norovirus challenge.
Norovirus infection is common among individuals through-
out the world, regardless of economic status, resulting in sig-
nificant morbidity and loss of productivity. Recent reports of
consecutive norovirus outbreaks on cruise ships, involving hun-
dreds of passengers and crew, garnered substantial media at-
tention and dramatically illustrate the potentially explosive
community spread of these viruses (8). Although the severity
of the disease is usually moderate and short term, an effective
vaccine would be advantageous to specific segments of the
population, such as food handlers, care providers, and military
personnel. The major obstacles to norovirus vaccine develop-
ment are the great degree of antigenic heterogeneity within the
family, the possibility that immunity to noroviruses may be
short-lived, and the lack of understanding of the correlates of
protective immunity. An effective vaccine should also provide
protective immunity against an ever-growing list of norovirus
strains. Evidence from outbreak investigations and human
challenge studies suggests that these viruses are highly infec-
tious, yet the biology and immunology of norovirus infection
remain poorly understood (32).
Noroviruses are members of the Caliciviridae family of sin-
gle-stranded, positive-sense RNA viruses. The majority of the
human noroviruses are classified into genogroup 1 (G1) and
G2 (47) Each of these genogroups is further divided into ge-
netic clusters. Norwalk virus (NV), Snow Mountain virus
(SMV), and Hawaii virus (HV) are the prototype strains of
genetic clusters G1.1, G2.2, and G2.1 and are the causative
agents of an estimated 5, 8, and 7% of norovirus outbreaks,
respectively (13). Strains within a genetic cluster typically show
80% amino acid identity in the major capsid protein se-
quence. Strains within the same genogroup show 60% iden-
tity, and strains in different genogroups show 50% identity.
This high degree of genetic variability translates into a high
degree of antigenic variability within the noroviruses.
Early human challenge studies demonstrated that some vol-
unteers remained uninfected even when challenged with high
doses of NV (30, 35), suggesting that some individuals may be
genetically resistant to NV infection. Recently, we demon-
strated that the FUT2 gene that encodes an 1,2-fucosyltrans-
ferase responsible for the histo-blood group antigen (BGA) H
type 1 is a susceptibility allele for NV infection (32). Volun-
teers who were homozygous for the inactive FUT2 allele were
resistant to infection at all dose levels studied. Other BGAs
displayed weak modulating effects on NV interaction and
pathogenesis. We and other groups have shown that NV virus-
like particles (VLPs) bind to H type 1-related BGAs secreted
in saliva (14, 20, 32) and membrane bound on mucosal cells
(34) and also to synthetic H type 1-related BGA (20, 24). This
H type 1-dependent in vitro binding pattern is so far restricted
to NV, as other strains of noroviruses demonstrate different
BGA binding affinities. Salivary binding assays have suggested
that SMV VLP binding is associated with expression of the B
BGA, while HV VLPs did not bind to any saliva sample (20).
These data suggest that noroviruses use multiple methods for
attachment to cells and hence for infection. It is unclear
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whether the FUT2 allele determines susceptibility to all noro-
virus infections.
Short-term immunity to NV has been observed in previous
human challenge studies (48). However, this immunity did not
necessarily extend to heterologous virus challenge, as volun-
teers who became ill upon challenge with NV also became ill
upon subsequent challenge with HV at the same rate as vol-
unteers not previously infected with NV (48). Further rechal-
lenge studies have shown that long-term immunity is not con-
ferred by a single NV challenge, as some volunteers who were
susceptible to an initial NV infection were susceptible to in-
fection in subsequent challenges 27 to 42 months later (41).
Previously, in both volunteer studies and outbreak investi-
gations, immunity to noroviruses has almost exclusively been
studied by monitoring serum immunoglobulin M (IgM) and IgG
responses to virus (35). IgM was shown to be a marker of re-
cent NV infection (5). In many studies, a fourfold increase in
anti-norovirus serum IgG titer has been considered indicative
of norovirus infection (17). Attempts to study fecal IgA in NV
infection have been unsuccessful in associating secretory IgA
(sIgA) with infection outcome (40). However, our recent study
utilizing saliva samples as a source of sIgA showed a correla-
tion between protection from NV infection and the presence of
a memory sIgA response in uninfected susceptible volunteers (32).
Importantly, some susceptible volunteers who were not infect-
ed did not have strong salivary IgA responses, indicating that non-
sIgA mechanisms are also involved in immunity to noroviruses.
In addition to antibody-producing B cells, T cells play an
important role in the control of viral pathogens. The cytokines
secreted by antigen-specific CD4 helper T cells guide the adap-
tive immune response. T helper 1 (Th1) and Th2 responses can
be activated by both the same and different epitopes within the
same pathogen, but one response type will often dominate over
the other. A Th2-favored immune response is primarily charac-
terized by interleukin 4 (IL-4) and IL-10 secretion by CD4 cells,
resulting in production of IgG2 and other anti-inflammatory fac-
tors. A Th1-favored response is primarily characterized by
secretion of gamma interferon (IFN-) by CD4 cells, result-
ing in macrophage activation, B-cell differentiation to IgG1
synthesis, and support for cytotoxic T lymphocytes (CTLs).
CTLs are important in the control of human immunodeficiency
virus (HIV) (4), Epstein-Barr virus (42), influenza virus (26),
lymphocytic choriomeningitis virus (52), and numerous other
viruses. To date, cellular immunity has not been studied fol-
lowing norovirus infection, but we expect effector T cells to
play a fundamental role in viral clearance and immunity.
In this study, we demonstrated that SMV infection was in-
dependent of secretor status and BGA expression and that the
serum IgG, salivary IgA, and effector T cells elicited following
infection were cross-reactive between strains within a genogroup
but not between strains in different genogroups. This is the first
study to examine the association between mucosal expression of
BGAs and infection with a G2 norovirus in humans and to
study T-cell activation after challenge with any live norovirus.
MATERIALS AND METHODS
Study design and subjects. A human challenge study was conducted to exam-
ine the infectivity of SMV. Fifteen healthy adult volunteers were admitted to the
University of North Carolina General Clinical Research Center (GCRC) for
collection of prechallenge samples and dosing. SMV inoculum was prepared
from stool filtrates and safety tested as reported for Norwalk virus (10), with
additional testing for other noroviruses, culturable human enteric viruses, hepatitis
A virus, HIV, coronavirus, astrovirus, adenovirus, rotavirus, cytopathic viruses, en-
dotoxins, common enteric pathogens (bacteria and protozoa), mycobacteria, and
Clostridium difficile toxin. Each volunteer received one dose of SMV (11) ranging
from 10 to 105 PCR detectable units, as defined by endpoint titration reverse tran-
scription (RT)-PCR (37). Dose levels were randomized, and no single dose level
was administered in sufficient numbers to validate statistical analysis of clinical
outcomes by dose. The study population was 47% male, 73% white, and 27%
other races, with an average age of 31 years (range 21 to 54). Volunteers remained
in the GCRC for the first 5 days postchallenge and returned for follow-up visits on
days 8, 14, and 21 postchallenge. During the first 7 days, all volunteer stools and
vomit were collected and stored at 4 or 20°C. Sera and saliva were collected daily
during the first 5 days postchallenge and at each follow-up visit. Samples were stored
at 20°C. PBMCs were harvested from whole blood collected prechallenge and on
days 8 and 21 postchallenge using a Ficoll-Pacque (Pharmacia-Amersham) gradient.
The cells were cryopreserved in 90% fetal calf serum–10% dimethyl sulfoxide until
they were used. All study protocols and methods were approved by the Univer-
sity of North Carolina School of Medicine Committee for Protection of Human
Subjects. All volunteers participated after providing informed consent.
Diagnosis of SMV infection. Volunteers were classified as infected if SMV
RNA was detected in any postchallenge stool sample by RT-PCR. All fecal
specimens were examined by RT-PCR using G2-specific primers located in the
RNA-dependent RNA polymerase gene (SR33/SR48) (1).
Measurement of anti-norovirus serum IgG. All sera were tested for anti-
norovirus IgG by ELISA using recombinant SMV, HV, or NV VLPs as the
antigen (20) and anti-human IgG (whole molecule)-alkaline phosphatase (Sigma
Chemicals) as the detector antibody. The VLPs used in this study were composed
of the open reading frame 2 (ORF2) major capsid protein from each strain
expressed in the VEE vector system and purified as reported previously (3, 20).
Seroconversion was defined as a 4-fold increase over the prechallenge titer in
postchallenge samples collected on either day 14 or 21, depending on patient
sample availability. By day 14 postchallenge, all nine of the infected volunteers
had a 4-fold increase over the prechallenge (day zero) anti-SMV serum IgG
titer. Titers remained at 4-fold above day zero levels for the duration of the
study. For IgG subclass determination, anti-IgG1-biotin or anti-IgG2-biotin an-
tibodies, followed by avidin-alkaline phosphatase (all from Sigma Chemicals),
were used as detector antibodies.
Histo-blood group antigen expression. Blood type was inferred from red blood
cell (RBC) (Ortho Clinical Diagnostics) hemagglutination by serum samples.
Secretor and Lewis phenotypes were determined from saliva by ELISA using
anti-Lewisa, anti-Lewisb, anti-A, and anti-B antibodies (Ortho Clinical Diagnos-
tics) (20). The secretor phenotype was confirmed by the FUT2 genotype (32).
Measurement of anti-norovirus and total salivary IgA. Saliva samples were
collected, processed, and assayed for anti-norovirus and total IgA by ELISA, as
described previously (32). Of the 15 sample sets collected, 12 were included in
the analysis. Three sample sets were eliminated from analysis because of poor
sample quality (total IgA  50 g/ml) (32). Conversion was defined as a 4-fold
increase over the prechallenge titer in postchallenge samples collected on either
day 14 or 21, depending on patient sample availability.
VLP stimulation of PBMCs. Cryopreserved peripheral blood mononuclear
cells (PBMCs) were thawed, washed with medium (RPMI 1640, 10% fetal calf
serum, 1% L-glutamine, 100 U of penicillin-streptomycin/ml), and dispensed into
96-well plates at 5  105 cells/well with either 10 ng of phorbol myristate acetate/
ml–0.5 g of ionomycin/ml, medium only, or 1 g of SMV, HV, or NV VLPs/ml.
The optimum cell number, stimulation time, and VLP concentration were deter-
mined empirically. The cells were stimulated for 48 h at 37°C in a 5% CO2 incubator
in duplicate or triplicate wells, depending on the number of available cells. Cell
culture supernatants were collected and stored at 20°C until they were used.
Measurement of cytokine secretion. Culture supernatants were simultaneously
analyzed for secreted Th1 cytokines (IFN-, tumor necrosis factor alpha [TNF-
], and IL-2) and Th2 cytokines (IL-4, IL-5, and IL-10) using the Cytometric
Bead Array (CBA) assay (BD Biosciences) as recommended by the manufac-
turer, with the exception that reagents were used at half the recommended
volumes. This change did not affect performance (P  0.92; Mann-Whitney
two-tail test). Inclusion of duplicate assay tubes did not significantly affect the
results (P  0.4065; Mann-Whitney two-tail test). Fluorescent beads were
counted on a BD Biosciences FacsCalibur flow cytometer, and data were ana-
lyzed using Cell Quest Software (BD Biosciences). In additional samples, IFN-
secretion was measured in duplicate by ELISA (BD Biosciences). The lower limit
of detection was 1 pg/ml for the CBA assay and 4 pg/ml for the IFN- ELISA.
Samples below these limits were assigned a value equal to half the lower limit of
detection for analysis purposes (43). For all samples, the medium-stimulated
background was subtracted.
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Depletion of CD4 or CD8 cells. PBMC samples were depleted of CD4 or
CD8 cells using antibody-coupled magnetic beads (Dynabeads; Dynal Biotech)
according to the manufacturer’s instructions. Depletion (90%) was monitored
by fluorescence-activated cell sorter analysis of the samples using anti-CD4–
fluorescein isothiocyanate and anti-CD8–phycoerythrin (Sigma Chemicals).
Statistical analysis. The Mann-Whitney two-tail test was used to compare the
median responses between groups. The Fisher exact test (Epi Info 2000; Centers
for Disease Control and Prevention) was used to test the association among
prechallenge IgG, blood type, sIgA, secretor and Lewis phenotypes, and risk of
infection.
RESULTS
Infectivity of SMV. Fifteen volunteers were dosed with SMV
and were classified as infected if viral RNA was detected in any
postchallenge stool sample by RT-PCR (10). Nine (60%) of
the volunteers became infected (Table 1). Of these, 7 (78%)
experienced symptoms of illness. Since NV infection has been
shown to be dependent upon expression of the BGA H type 1
(32), we examined the effect of BGA expression on SMV in-
fection. Expression of BGA on RBCs (blood type) was deter-
mined by RBC hemagglutination. Mucosal-cell expression of
BGA (secreted BGA) was determined by ELISA of saliva
samples, as reported previously (32). In contrast to NV infec-
tion, volunteers from every blood type, secretor phenotype,
and Lewis type became infected. SMV infection was not asso-
ciated with blood type (P  0.608), secretor phenotype (P 
0.525), or Lewis phenotype (P  0.505) (Table 1). These data
likely indicate that NV and SMV strains use different mecha-
nisms for infection, independent of the secretor phenotype.
Serum IgG response to SMV challenge. Seroconversion, a
4-fold increase over the prechallenge serum IgG titer, has
been used to define norovirus infection in challenge studies
and outbreak investigations (18, 11). By day 14 postchallenge,
all nine of the infected volunteers had a 4-fold increase over
the prechallenge (day zero) anti-SMV serum IgG titer, verify-
ing the association between virus excretion and seroconver-
sion. There was no significant difference between the titers of
prechallenge SMV-reactive IgG in infected and uninfected
volunteers (P  0.215) (Fig. 1), suggesting that the prechal-
lenge anti-SMV IgG titer is not predictive of the risk of SMV
infection. The infected volunteers had postchallenge (day 14 or
21) anti-SMV IgG titers that were significantly higher than
prechallenge titers (P  0.0004), with a median 23.8-fold in-
crease (range, 4.9- to 91.8-fold). The uninfected volunteers did
not have a significant rise from the prechallenge titer, with a
median change in the anti-SMV IgG titer of 1.5-fold (range,
TABLE 1. SMV infection is not associated with blood type,
secretor phenotype, or Lewis phenotype
Parameter No. infecteda No. uninfected % Infected
Blood type
O 4 4 50
A 2 2 50
B 1 0 100
AB 2 0 100
Total 9 6 60
Secretor type
Positive 8 4 67
Negative 1 2 33
Lewis type
Positive 7 6 64
Negative 1 0 100
a Viral RNA detected in stool.
FIG. 1. SMV elicits a cross-reactive serum IgG response in challenged volunteers. Pre- and postchallenge sera from each volunteer were tested
for anti-SMV, anti-HV, and anti-NV IgG by ELISA. *, P  0.05. Also shown are the percentages of volunteers with a 4-fold increase over the
day zero titer. The error bars indicate standard deviations.
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0.8- to 2.0-fold) (Fig. 1 and data not shown). Seroconversion
was highly predictive of infection (P  0.0002).
Cross-reactivity of serum IgG after SMV challenge. Serum
samples collected during outbreak investigations have shown
that some norovirus strains share cross-reactive epitopes (18,
19). This observation may in part explain our results indicating
that the prechallenge anti-SMV IgG titer was not predictive of
SMV infection. To investigate the cross-reactivity of serum
IgG generated after SMV challenge, prechallenge and post-
challenge (day 14 or 21) serum samples from each volunteer
were also tested for anti-HV and anti-NV IgG by ELISA (Fig.
1). As described above for anti-SMV IgG, there were no sig-
nificant differences between prechallenge titers of anti-HV IgG
(P  0.8572) or anti-NV IgG (P  0.8572) in infected and
uninfected volunteers. After challenge, infected volunteers had
postchallenge titers of anti-HV IgG (P  0.0173) that were
significantly higher than prechallenge titers (Fig. 1). Three
(33%) of the SMV-infected volunteers had 4-fold increases,
and an additional two volunteers had a 3-fold increase in
anti-HV IgG. One volunteer produced a response with greater
reactivity to HV than SMV. In contrast to the response to HV
antigen, SMV infection did not result in a significant increase
in anti-NV IgG (P  0.90), suggesting that cross-reactive IgG
responses are genogroup specific. Among the uninfected vol-
unteers, significant increases over the prechallenge titers were
not detected in anti-HV IgG (P  0.5755) or anti-NV IgG (P
 0.69) titers. None (zero of six) of the uninfected volunteers
seroconverted to HV. One (one of six) uninfected volunteer
did produce antibody to NV (Fig. 1). The group difference
between pre- and postchallenge NV IgG titers was not signif-
icant. These data suggest four important points: (i) SMV in-
fection, not just exposure, is essential for activation of an
anti-SMV serum IgG response, even in volunteers with pre-
challenge anti-SMV-reactive IgG; (ii) IgG elicited during an
SMV infection is cross-reactive with VLPs from strains within
the genogroup but not across genogroups; (iii) SMV and HV
share some cross-reactive epitopes, and prechallenge IgG mea-
surements reflect the sum of cross-reactive epitopes among the
noroviruses each volunteer has previously encountered and
should not be considered strain-specific IgG; and (iv) occasion-
ally, a heterotypic IgG response may dominate following no-
rovirus challenge, reminiscent of a response influenced by ex-
posure history.
Salivary IgA response to SMV challenge. Norovirus infec-
tion is likely limited to the gut; thus, mucosal antibodies may
be important in protection from infection (32). To measure the
mucosal immune response to SMV challenge, salivary samples
from 12 volunteers were assayed for anti-SMV and total IgA by
ELISA, and the ratio of the two measurements was used for
comparisons. As with serum IgG, there was no significant dif-
ference between the prechallenge salivary mucosal IgA ratios
in infected and uninfected volunteers (P  0.4237). However,
infected volunteers had anti-SMV sIgA titers on day 14 or 21
postchallenge (P  0.0308) that were significantly higher than
prechallenge titers and had a median 6-fold increase (range,
1.5- to 36.8-fold) (Table 2). Four out of six (67%) infected vol-
unteers had a 4-fold increase in anti-SMV sIgA titer. Unin-
fected volunteers did not have a significant rise in anti-SMV
sIgA titer (median, 1.4-fold increase; range, 0.64- to 2.0-fold)
(Table 2). As with serum IgG, a 4-fold increase in anti-SMV
sIgA by day 14 or 21 postchallenge was associated with infec-
tion (P  0.0278).
Cross-reactivity of salivary IgA after SMV challenge. To
investigate the cross-reactivity of salivary IgA generated after
SMV challenge, prechallenge and convalescent-phase saliva
samples from five infected volunteers and the one uninfected
volunteer who seroconverted to NV were measured for an-
ti-HV and anti-NV sIgA, and the ratio of anti-norovirus sIgA
to total sIgA was determined (Table 2). One infected volunteer
had a 4-fold increase in salivary IgA reactive to HV. None of
the infected volunteers had a 4-fold increase in salivary IgA
reactive to NV. A 3-fold increase in anti-HV and anti-NV
sIgA was observed in another infected volunteer. Fewer vol-
unteers had a 4-fold increase in HV-reactive sIgA compared
to IgG. This result may reflect the higher titer of antibody
found in serum versus saliva, as opposed to suggesting that
sIgA is more strain specific than IgG.
SMV challenge elicits a Th1 immune response. The cellular
immune response to norovirus challenge has not been studied
previously. However, the role of T cells in some human viral
infections has been described (27). To begin to characterize
the cellular immune response elicited by SMV challenge,
PBMCs were collected from whole blood prechallenge and on
days 8 and 21 postchallenge and cryopreserved for in vitro VLP
stimulation followed by analysis of secreted cytokines. Eleven
volunteers had at least partial PBMC sample sets. Three in-
fected and two uninfected volunteers had complete sample
sets. PBMCs from these five volunteers were stimulated with 1
g of SMV VLPs/ml for 48 h, and the clarified tissue culture
supernatants were assayed for Th1 cytokines (IFN-, TNF-,
and IL-2) and Th2 cytokines (IL-10, IL-5, and IL-4) using the
flow cytometry-based CBA assay (Fig. 2). Cytokine responses
TABLE 2. Anti-norovirus salivary IgA response





Prechallengec 0.12 (0.04–1.21) 0.24 (0.07–0.73)
Postchallenged 0.85 (0.33–1.84) 0.22 (0.16–1.2)
Increasee 5.6g (1.5–36.8) 1.4 (0.64–2.0)
Volunteers converted (%)f 67 0
Anti-HV IgAh
Prechallenge 0.06 (0.03–0.32) 0.15
Postchallenge 0.19 (0.13–0.28) 0.15
Increase 2.2 (0.8–9.3) 1.0
Volunteers converted (%) 20 0
Anti-NV IgAh
Prechallenge 0.03 (0.008–0.06) 0.06
Postchallenge 0.07 (0.005–0.12) 0.07
Increase 2.3 (0.63–3.0) 1.2
Volunteers converted (%) 0 0
a Viral RNA detected in stool.
b (Microgram of VLP-reactive salivary IgA per milliliter/microgram of total
salivary IgA per milliliter)  100. n  6.
c Day zero.
d Day 14 or 21.
e Median of individual increases (n-fold) above prechallenge titer.
f Percentage of volunteers with 4-fold increase over the prechallenge titer.
g P  0.05.
h n  5 (infected); n  1 (uninfected).
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were compared by group using the Mann-Whitney two-tail test. In
both the infected and uninfected volunteers tested, the greatest
cytokine response to SMV VLP stimulation was increased IFN-
secretion (P  0.0121, comparing median concentrations of se-
creted IFN- from prechallenge PBMCs to those from peak [day
8 or 21] postchallenge PBMCs). Each volunteer demonstrated a
rise in IFN- secretion (median increase, 20.0-fold [range, 6.1- to
6,003-fold]). Smaller, but significant, rises above the prechallenge
titer were also detected for IL-2 (P  0.0121), with a median
increase of 5.5-fold (range, 4.2- to 276.8-fold), and IL-5 (P 
0.0121), with a median increase of 4.2-fold (range, 4.1- to 16-fold).
The timing (day 8 or 21) of peak cytokine up-regulation varied
between different volunteers regardless of their infection sta-
tus. Significant changes were not detected between prechal-
lenge and postchallenge PBMC secretion of TNF-, IL-10, or
IL-4, although some individual responses were elevated (Fig.
2). The lack of a TNF- response was somewhat surprising, since
TNF- and IFN- are often correlated (44), and it may reflect the
small sample size of our population. Increased IL-5 is a marker
for a Th2 response. The response shown here is statistically sig-
nificant, even though the absolute concentration of IL-5 detected
was low (median, 3.7 pg/ml), especially in comparison to IFN-
secretion (median, 3,002 pg/ml), as described for rhinovirus-stim-
ulated PBMCs (6). These data indicate a predominant, but not
exclusive, Th1 cellular immune response to SMV challenge.
The enhanced secretion of IFN- in SMV-stimulated
PBMCs from both infected and uninfected volunteers sug-
gested that measurement of IFN- levels could provide a quan-
titative indication of cellular immune response in all SMV-
challenged volunteers. Thus, secreted IFN- was measured by
ELISA for the 11 volunteers with at least two PBMC collec-
tions available for comparison (Fig. 3 and data not shown).
Four out of six uninfected and all seven infected volunteers
had PBMCs collected prechallenge. All four (100%) of the
uninfected and six of the seven (86%) infected volunteers had
prechallenge SMV-reactive cells that secreted IFN- in re-
sponse to in vitro SMV stimulation, suggesting previous noro-
virus exposure and immunological memory in 91% of the chal-
lenged volunteers. There was no significant difference between
prechallenge IFN- secretion levels in the infected (median,
73 pg/ml) and uninfected (median, 264 pg/ml) volunteers (P 
0.1738). Among the seven infected volunteers, a significant
change from prechallenge IFN- secretion was detected in
postchallenge PBMC samples (P  0.0105), with a median
increase of 33.2-fold (range, 0.61- to 3,025-fold) (Fig. 3). Five
of the seven infected volunteers (71%) had a 4-fold increase
over prechallenge IFN- secretion in postchallenge PBMC
samples. Among the four uninfected volunteers, two (50%)
had a 4-fold increase over prechallenge IFN- secretion, with
a median increase of 3.0-fold (range, 0.02- to 14-fold) (Fig. 3).
As noted for the five volunteer samples analyzed by CBA, peak
up-regulation of cytokine secretion (day 8 or 21) between dif-
ferent volunteers varied regardless of their infection status.
To further address the nature of the SMV-induced immune
response, prechallenge and postchallenge serum samples were
tested for IFN-, IL-2, IL-6, and IL-10 by ELISA. Significant
increases in both IFN- (median increase, 10.9-fold; range, 1.0-
to 966-fold [P  0.0117]) and IL-2 (median increase, 4.8-fold;
range, 1.0- to 141.6-fold [P  0.0093]) concentrations in serum
were detected in acute-phase (day-2) serum samples collected
from infected volunteers. Significant changes in cytokines were
not detected in IL-6 or IL-10 in sera from infected volunteers
or in any cytokine in serum samples from uninfected volun-
teers. Furthermore, prechallenge and postchallenge serum sam-
FIG. 2. SMV challenge elicits a predominately Th1 cytokine response. PBMCs from two uninfected and three infected SMV-challenged
volunteers were collected prechallenge and on days 8 and 21 and stimulated with SMV VLPs, and the culture supernatants were analyzed for
secreted Th1 cytokines (IFN-, TNF-, and IL-2) and Th2 cytokines (IL-4, IL-5, and IL-10) using the CBA assay. The data shown represent day
zero compared to the peak day of cytokine secretion for each volunteer (day 8 or 21). *, P  0.05. Also shown are the percentages of volunteers
with a 4-fold increase over the day zero titer. The error bars indicate standard deviations.
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ples from infected volunteers were tested for anti-SMV IgG1 and
IgG2. In agreement with previous studies of anti-norovirus IgG
subclass distribution (2, 21), most of the detectable response
was an increase in IgG1 (median increase, 3.99-fold; range, 0.16-
to 19.5-fold). Little change in anti-SMV IgG2 titer was detected
(median increase, 1.03-fold; range, 0.98- to 6.4-fold). These acute-
phase serum cytokine and IgG subclass data support the
PBMC-secreted cytokine data, indicating that the SMV-in-
duced immune response is weighted toward a Th1 response.
Five of the seven infected volunteers (71%) had a 4-fold
increase over prechallenge IFN- secretion in postchallenge
PBMC samples. Suppression of IFN- responses by other cy-
tokines has been reported in some HIV-infected individuals
(16). To determine if additional cytokines could explain the
lack of response in the two infected IFN- nonresponders
(data not shown), culture supernatants from the infected non-
responders were assayed for additional cytokines using the
CBA assay (data not shown). One volunteer was found to be
producing low levels of the Th1 cytokines IFN- (4.9-fold in-
crease over the prechallenge titer), TNF- (4.2-fold increase),
and IL-2 (2.2-fold increase). No changes in Th2 cytokines were
detected, indicating that infection in this volunteer did elicit a
weak Th1-type immune response. In the other infected non-
responder, IL-10 was the only cytokine response detected (4.9-
fold increase), identifying this volunteer as the only infected
IFN- nonresponder. Among the three uninfected nonre-
sponders, no additional cytokines were detected by CBA anal-
ysis (data not shown), supporting previous results suggesting
multiple mechanisms for resistance to norovirus infection (32).
SMV challenge elicits a cross-reactive T-cell response. Anal-
ogous to our studies of antibody epitopes cross-reactive be-
tween norovirus strains, the cross-reactivity of the Th1 cellular
response elicited by SMV challenge was investigated. PBMCs
from the two uninfected and three infected volunteers (as seen
in Fig. 2) who responded to SMV challenge with increased
IFN- secretion were stimulated separately with HV and NV
VLPs, and the culture supernatants were assayed for IFN-,
TNF-, IL-2, IL-10, IL-5, and IL-4 using the CBA assay (Fig.
4). After stimulation with HV, postchallenge PBMCs from the
infected and uninfected volunteers secreted significantly more
IFN- than prechallenge PBMCs (P  0.0214), with a median
increase of 10.7-fold (range, 3.2- to 2,086-fold), and IL-2 (P 
0.0121), with a median 3.8-fold increase (range, 2.2- to 180.6-
fold) (Fig. 4A). Significant differences were not detected in the
other cytokines, indicating that the Th1 response mounted to
SMV was cross-reactive with HV (Fig. 4A). In contrast, after
NV VLP stimulation, no significant changes were detected
between prechallenge and postchallenge PBMCs in the ability
to secrete IFN-, IL-2, TNF-, IL-10, or IL-4. There was
significantly increased secretion of IL-5 in response to NV
VLP stimulation (P  0.0477), but the concentrations detected
were low, as noted for SMV stimulation (Fig. 4B).
To further study the cross-reactivity of the Th1 response
generated after SMV challenge, culture supernatants from ad-
ditional PBMCs stimulated with HV or NV VLPs were assayed
for secreted IFN- by ELISA (Fig. 3). Ten volunteers had
PBMCs available for the cross-reactivity studies. Those volun-
teers who did not respond to SMV did not respond to HV or
FIG. 3. PBMCs from both infected and uninfected volunteers secrete IFN- after VLP stimulation. PBMCs collected pre- and postchallenge
from SMV-challenged volunteers were stimulated separately in vitro with SMV, HV, or NV VLPs, and the culture supernatants were analyzed for
secreted IFN- by ELISA. The data shown represent day zero compared to the peak day of cytokine secretion for each volunteer (day 8 or 21).
*, P  0.05. Also shown are the percentages of volunteers with a 4-fold increase over the day zero titer. The error bars indicate standard deviations.
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NV after SMV challenge (data not shown). Volunteers who
had a significant increase in SMV-induced IFN- secretion
post-SMV challenge also had a significant increase in response
to HV stimulation (P  0.0131), but not to NV stimulation
(P  0.631). Among the six infected volunteers, three (50%)
had a 4-fold increase in IFN- secretion after HV stimula-
tion, with a median increase of 61-fold (range, 0.17- to 183-
fold) (Fig. 3). There was a median increase of 1.6-fold (range,
0.06- to 5.37-fold) among the four uninfected volunteers, and
one volunteer had a 4-fold increase in IFN- secretion after
HV stimulation (Fig. 3). None of the uninfected volunteers
had a 4-fold increase in IFN- secretion after NV VLP stim-
ulation. The median change was 0.58-fold (range, 0.11- to
1.3-fold) (Fig. 3). As identified with antibody responses, some
SMV-induced Th1 cells cross-react with HV but not NV, in-
dicating that strains of the same genogroup share common
epitopes that may elicit cross-protection.
IFN- secretion is dependent upon CD4 cells. Both CD4
and CD8 T cells secrete IFN- (44). Since our method of
antigen presentation relies on VLP uptake, processing, and
presentation by antigen-presenting cells within the PBMCs, a
bias toward detection of CD4 cells may be expected, although
other means of presentation could also occur (44). To identify
the cellular source of the Th1 cytokines produced in response
to SMV challenge, PBMCs collected on day 8 or 21 postchal-
lenge from five volunteers (three infected and two uninfected)
were depleted of either CD4 or CD8 cells via antibody-
coupled magnetic beads (15) and stimulated with SMV, and
the culture supernatant was assayed for secreted IFN- (Fig.
5). Cell depletion (90%) was monitored by fluorescence-
activated cell sorter analysis of depleted and nondepleted cul-
tures (data not shown). Depletion of CD8 cells did not have
a significant effect on IFN- secretion (P  0.6745). However,
it is noteworthy that in the two uninfected volunteers (SM07
and SM08 in Fig. 5), depletion of CD8 cells led to increased
IFN- secretion after stimulation, suggesting that in these two
uninfected volunteers, CD8 cells may be down-regulating the
IFN- response in vitro (16), possibly providing a balanced
immune response to a neutralized virus. In contrast, depletion
of CD4 cells before SMV stimulation resulted in a significant
decrease in IFN- secretion after stimulation in all of the
volunteers tested (P  0.0214). IFN- secretion decreased an
average of 93% (range, 81.5 to 97%) when CD4 cells were
absent from the PBMC culture during stimulation (Fig. 5),
identifying CD4 cells as the primary source of IFN- secre-
tion in PBMCs stimulated in vitro with norovirus VLPs.
DISCUSSION
Human challenge studies have indicated that a subset of
individuals may be genetically resistant to noroviruses (30, 35).
The characterization of the BGA H type 1 as a ligand that
FIG. 4. SMV challenge elicits a cross-reactive, predominately Th1
cytokine response. PBMCs from two uninfected and three infected
SMV-challenged volunteers were collected prechallenge and on days 8
and 21 and stimulated separately in vitro with HV VLP (A) or NV
VLP (B), and the culture supernatants were analyzed for secreted Th1
cytokines (IFN-, TNF-, and IL-2) and Th2 cytokines (IL-4, IL-5, and
IL-10) using the CBA assay. The data shown represent day zero com-
pared to the peak day of cytokine secretion for each volunteer (day 8
or 21). *, P  0.05. Also shown are the percentages of volunteers with
a 4-fold increase over the day zero titer. The error bars indicate
standard deviations.
FIG. 5. CD4 T cells secrete IFN- after SMV challenge. PBMCs
collected postchallenge from two uninfected (SM07 and -08) and three
infected (SM10, -11, and -15) SMV-challenged volunteers were de-
pleted of CD4 or CD8 cells using antibody-coupled magnetic beads.
The depleted cells were stimulated in vitro with SMV VLPs, and the
culture supernatants were analyzed by ELISA for secreted IFN-.
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binds NV VLPs (34) led to the observation that individuals
who do not express H type 1 (the secretor-negative phenotype)
do not become infected with NV even when challenged at very
high doses (32), establishing FUT2 as a susceptibility gene for
NV and suggesting that H type 1 may be a receptor for virus
entry. Further work with other norovirus strains has demon-
strated that the noroviruses can use a wide range of molecules
in the histo-blood group antigen family as ligands (20, 22). In
contrast to NV, SMV infection was not associated with the
presence of a functional FUT2 gene or with expression of any
of the H type 1-related molecules, as one of three secretor-
negative volunteers became infected with SMV. The effect of
the BGA genes on SMV infection will need to be further
studied in subsequent human challenge studies with larger
groups with varied antigen expression. The small number of
subjects characterized here is not sufficient to identify genes
with weak penetrance, as was noted for the effect of B antigen
expression and NV infection (32, 23). Moreover, our data
indicate that saliva-VLP binding cannot predict norovirus sus-
ceptibility as strictly as suggested (22) and that virus binding
and entry mechanisms may be considerably more complex.
In these studies, we used VLPs as the source of norovirus
antigen. These VLPs are composed of the major capsid protein
expressed from ORF2 of SMV, HV, or NV. While morpho-
logically and antigenically very similar to native virions (29),
they do not represent the entire norovirus strain genome, and
thus, any immune response measured represents a partial re-
sponse. Furthermore, the cross-reactivities of antibodies and T
cells measured here are dependent upon several factors, in-
cluding the degree of genetic relatedness between strains and
the major histocompatibility complex (MHC) haplotype of
each volunteer, as some MHC haplotypes may preferentially
present peptides that are not conserved between strains from
different genetic clusters (9, 36).
All of the SMV-infected volunteers and none of the unin-
fected volunteers produced a significant serum IgG response to
SMV, indicating that SMV infection, not just exposure, is es-
sential for activation of an anti-SMV serum IgG response, as
reported for NV (32). Furthermore, the IgG elicited during an
SMV infection cross-reacts with another strain within G2 but
not with a G1 strain, supporting previous findings (28, 39).
While these results provide a description of the antigenic re-
latedness of these viral strains to each other and an assessment
of general norovirus exposure in the past, interpretation of
their relevance to vaccine design and outbreak investigations is
complicated. Studies have used the presence of a norovirus
VLP-reactive IgG titer as an indication of strain exposure.
However, the cross-strain reactivity of anti-norovirus IgG
shown here makes it difficult to determine the infection strain
history, as proposed earlier (12, 32). This point is particularly
important in outbreak investigations, where, in our experience,
more subjects are willing to donate serum samples than are
willing to donate stool samples for diagnosis. The data pre-
sented here suggest that strain identification by serum IgG titer
increase would be imprecise. A comprehensive panel of VLPs
and refined diagnostic tests will be needed before IgG can be
used to unravel prechallenge histories and current infections
with norovirus.
Furthermore, data indicating that a subset of uninfected
SMV- and NV-challenged volunteers mount a cellular immune
response and a mucosal IgA response, respectively, after no-
rovirus challenge support earlier work suggesting that some
volunteers are uninfected due to protective immunity (32).
None of these “protected” volunteers produced IgG reactive
with the challenge strain. It is possible that a pathogen limited
to the gut mucosal surface without a systemic distribution may
not be significantly affected by serum IgG. Elegant studies of
rotavirus infection in gnotobiotic piglets have shown that sIgA,
not neutralizing IgG, correlated with protection from rotavirus
reinfection (49–51). Concordant with these findings, NV-chal-
lenged susceptible volunteers who produced sIgA within the
first 5 days after viral challenge were less likely to become
infected than susceptible volunteers who did not produce sIgA,
indicating that memory sIgA may be a component of protective
immunity to NV infection (32). However, this early sIgA re-
sponse was not detected in all of the susceptible uninfected
volunteers. Thus, other mechanisms must participate in pro-
tection against norovirus infection as well. Although the num-
bers are small, among the SMV-challenged uninfected volun-
teers, an early (day 1 to 5) sIgA response was not detected,
supporting earlier evidence that multiple mechanisms of pro-
tection from noroviruses exist (32).
This is the first reported characterization of the Th1 and Th2
cellular immune responses to any live norovirus challenge.
PBMCs were stimulated in vitro with intact VLPs (43) from
three norovirus strains. This approach allowed antigen-pre-
senting cells to internalize native conformation protein, digest
it, and present it in the context of syngeneic MHC class II, as
would occur in vivo during challenge, resulting in norovirus-
specific CD4-T-cell activation (44). Comparison of Th1 and
Th2 cytokines produced after SMV stimulation of PBMCs
indicated that the Th response to SMV was weighted toward a
Th1 response, with significant increases in secretion of IFN-
and IL-2 and serum IgG1 production, similar to results seen in
a subset of NV VLP-challenged volunteers (46). These cyto-
kines enhance macrophage activation and production of IgG
subclasses that favor opsonization and support CD8 cytotoxic
T cells (27). IFN- was up-regulated postchallenge in most of
the volunteers, regardless of infection. Both infected and un-
infected volunteers could be classified as responders or non-
responders based on a 4-fold increase in IFN- secretion
postchallenge. The elapsed time between challenge and the
first postchallenge PBMC sample (8 days) may have been too
great to allow identification of a difference in the timing of
activation of the Th1 cells between the infected and uninfected
volunteers. Furthermore, the T cells examined here were col-
lected from blood, while memory T cells to a mucosal patho-
gen would be located primarily at the site of initial antigen
encounter, the gut-associated mucosa (25). Analyses of cyto-
kines and IgG subclasses in daily serum samples support the
hypothesis of a preferential but not exclusive Th1 cytokine
response following SMV challenge. Increases in both IFN-
and IL-2 were detected during the initial 48 h postchallenge,
and the IgG response was IgG1, with little change in the IgG2
titer in serum samples from the infected volunteers. Further-
more, the only Th2 cytokine in which significant increases were
detected after SMV challenge was IL-5, associated with en-
hanced sIgA production. sIgA has been shown to be associated
with protection from NV infection among susceptible volun-
teers (32). Identification of IL-5 secretion by postchallenge
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PBMCs in response to SMV and NV in vitro stimulation sup-
ports the hypothesis that the mucosal immune response plays
an important role in norovirus infection. Additional human
challenge studies will be needed to decipher the roles of sIgA
and the Th2 immune response in protection from norovirus.
Future studies should include measurement of gut cytokine
profiles and evaluation of PBMCs collected soon after infec-
tion to accurately determine the importance of Th2 responses
to infection.
Although these experiments do not address SMV protective
immunity, the Th1 response identified in a subset of uninfected
volunteers suggests that activation of a Th1 cellular immune
response may be associated with protection from infection
after challenge in some SMV-susceptible volunteers. Support-
ing a role for the Th1 response in mediating SMV infection
outcome, the only infected volunteer without an increase in
IFN- secretion after SMV challenge produced IL-10 (data
not shown), suggesting that the Th1 response elicited by SMV
in the other infected volunteers was being suppressed. This
volunteer had high prechallenge titers of HV-reactive serum
IgG and salivary IgA and Th1 cytokine secretion. These high
titers decreased throughout the course of the study, suggesting
that this volunteer had experienced a recent infection with HV
or a closely related strain of norovirus before entering the
SMV study. SMV-reactive IgG developed normally over time
and in magnitude, but the volunteer did not develop a salivary
IgA or Th1 immune response to SMV after infection. Al-
though speculative, these data provide suggestive evidence that
previous viral infection history may affect the immune response
to a current norovirus challenge, as has been shown for dengue
serotypes (38) and between lymphocytic choriomeningitis and
vaccinia virus infections (31). Clearly, further studies are
needed to identify the components of protective immunity and
the effect of previous exposure history on infection outcome.
No change in T-cell cytokine secretion, serum IgG, or sali-
vary IgA was detected in any of the uninfected volunteers who
did not respond to SMV challenge with enhanced IFN- se-
cretion (three volunteers). Lack of activation of an adaptive
immune response, as seen in the other three uninfected vol-
unteers who received at least the same dose level, suggests that
these volunteers were protected by another mechanism, such
as innate immunity or inherent genetic resistance to the virus
(lack of receptors), or that the SMV ORF2 capsid may not be
as antigenic for the HLA haplotype of these volunteers, ham-
pering our ability to detect an immune response (9, 36).
Importantly, the cellular response elicited by SMV challenge
was cross-strain reactive with HV but not NV, suggesting that
the antigenic relatedness of the strains we examined mirrored
the genetic relatedness. These data are in agreement with
previous studies of strain-cross-reactive Th1-mediated re-
sponses in HIV (7), dengue virus (33), and influenza virus (26).
Additional G1 and G2 VLPs are needed to assess the T-cell
cross-reactivity between genoclusters and genogroups, given
the high degree of genetic heterogeneity among norovirus
strains. In addition to the capsid protein, ORF3 and nonstruc-
tural proteins should be examined as a source of cross-reactive
T-cell antigen, as anti-influenza A virus (26) and anti-cytomeg-
alovirus (45) CTLs recognized internal antigens and were sub-
type cross-reactive.
The data provided here indicate that antibody and cellular
immune responses generated after SMV challenge are cross-
reactive within genogroups. Production of new inocula of ad-
ditional norovirus strains representing different genetic clus-
ters and further human challenge studies are needed to define
the antigenic relationships among strains and the components
of protective immunity to each and to determine if specific
heterotypic immune responses are cross-protective.
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